Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Go back to Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 112.45 +2.77 (2.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $109.68 | 52 Week High | $18.39 | |||
| Open | $109.72 | 52 Week Low | $6.96 | |||
| Day High | $112.66 | P/E | N/A | |||
| Day Low | $109.38 | EPS | $-0.58 | |||
| Volume | 10,348,639 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 125.31 -2.31 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.62 | 52 Week High | $118.49 | |||
| Open | $127.85 | 52 Week Low | $55.00 | |||
| Day High | $128.72 | P/E | N/A | |||
| Day Low | $125.23 | EPS | $-0.56 | |||
| Volume | 3,700,361 | |||||
